Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
NCT02189343
Completed
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2019
Locations: UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas +1 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
NCT00401843
Completed
The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab (CNTO 328) and bortezomib (Velcade). The purpose of Part 2 of the study is to compare the length of progression free survival for those patients given CNTO 328 and bortezomib to those patients given bortezomib alone.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/07/2019
Locations: Not set, Dallas, Texas +1 locations
Conditions: Multiple Myeloma
Register for Updates
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
NCT00004228
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/24/2019
Locations: Texas Tech University Health Sciences Center School of Medicine - Amarillo, Amarillo, Texas +11 locations
Conditions: Lymphoma
Register for Updates
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT02159365
Completed
To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2019
Locations: Texas Oncology, Dallas, Texas +5 locations
Conditions: Multiple Myeloma
Register for Updates
A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block
NCT02151487
Completed
The aim of this randomized, observer-blinded study is to evaluate the postoperative analgesic efficacy of adding dexamethasone and clonidine to ropivacaine in supraclavicular nerve block. The investigators hypothesized that addition of dexamethasone and clonidine to ropivacaine would prolong the duration of analgesia in supraclavicular nerve block compared with ropivacaine alone.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/15/2019
Locations: Parkland Health Hospital System, Dallas, Texas
Conditions: Upper Extremity Surgery
Register for Updates
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT01846611
Completed
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/29/2019
Locations: Not set, Austin, Texas +7 locations
Conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Register for Updates
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
NCT01383928
Completed
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) in phase 1 and to determine the combined response rate of clinical response CR and very good partial response (VGPR) in phase 2 of oral (PO) ixazomib administered twice-weekly in combination with lenalidomide and low-dose dexamethasone in a 21-day cycle in participants with newly diagnosed multiple myeloma (NDDM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2019
Locations: Baylor Sammons Cancer Center, Dallas, Texas
Conditions: Multiple Myeloma
Register for Updates
Dexamethasone Therapy in VLBW Infants at Risk of CLD
NCT00011362
Completed
Infants who are on breathing support are often treated with steroids (dexamethasone); however, the best timing of therapy is not known. This trial looked at the benefits and hazards of starting dexamethasone therapy at two weeks of age and four weeks of age in premature infants.
Gender:
ALL
Ages:
Between 13 days and 15 days
Trial Updated:
03/20/2019
Locations: University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Register for Updates
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048
Completed
The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time before myeloma worsens \[progression free survival (PFS)\].
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2018
Locations: Charles A. Sammons Cancer Center, Dallas, Texas +1 locations
Conditions: Multiple Myeloma
Register for Updates
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
NCT01983449
Completed
To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically significant lesion in the superficial femoral and/or popliteal arteries. Study Drug and Dose: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/ml, with dilute contrast (17%) administered to the adventitia in a dose of 1.6 mg per cm of desired vessel treatment length.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2018
Locations: DFW Vascular Group, Dallas, Texas +3 locations
Conditions: Peripheral Arterial Diseases
Register for Updates
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
NCT01002248
Terminated
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2018
Locations: Not set, Bedford, Texas +6 locations
Conditions: Multiple Myeloma
Register for Updates
Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial)
NCT01238536
Completed
The broad, long-term objective of this research protocol is to improve the quality of life for patients suffering from lumbar spinal stenosis. This objective will be met by examining the safety and clinical efficacy of epidural steroid injections for treatment of pain associated with lumbar spinal stenosis. This prospective, randomized, double-blind controlled trial (RCT) will test the hypothesis that the effectiveness of epidural steroid injections (ESI) plus local anesthetic (LA) is greater th... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
11/15/2017
Locations: Dallas VA Medical Center, Dallas, Texas
Conditions: Spinal Stenosis, Low Back Pain
Register for Updates